

Hanger Lane  
Ealing  
London W5 3QR  
UK

T: +44 (0)20 8799 8200  
F: +44 (0)20 8799 8201  
E: enquiries@antisoma.com  
W: www.antisoma.com

RECEIVED

2007 FEB 16 A.T.F. 13

OFFICE OF INTERNATIONAL  
CORPORATE FINANCE

**ANTISOMA**

Exemption number: 82-34926

Office of International Corporate Finance  
Division of Corporate Finance  
Mail Stop 3628  
United States Securities and Exchange Commission  
100 F Street, NE  
Washington, D.C. 20549  
U.S.A.



07021081

**SUPPL**

Wednesday 7 February 2007

Ladies and Gentlemen:

**Antisoma plc**

Pursuant to Rule 12g3-2(b) under the United States Securities Exchange Act of 1934, as amended (the "Exchange Act"), we hereby furnish you with certain documentation that we have made public or filed with the UK Listing Authority, the London Stock Exchange or the Registrar of Companies for England and Wales at Companies House or distributed to our shareholders and which is listed in Annex 1 to this letter.

These documents supplement the information previously provided with respect to Antisoma plc's request for exemption under Rule 12g3-2(b), which was established on November 21, 2005.

This information is being furnished with the understanding that such information and documents will not be deemed "filed" with the SEC or otherwise subject to the liabilities of Section 18 of the Exchange Act, and that neither this letter nor the furnishing of such documents and information shall constitute an admission for any purpose that Antisoma plc is subject to the Exchange Act.

Please do not hesitate to contact the undersigned at +44 20 8799 8200 in the United Kingdom if you have any questions.

Thank you for your attention.

Yours faithfully  
For and on behalf Antisoma plc

Name: Simone Tinney  
Title: Communication Assistant

PROCESSED

FEB 16 2007

THOMSON  
FINANCIAL

**Antisoma to present at the BIO CEO conference**

**7 February 2007, London, UK** – Cancer drug developer Antisoma plc (LSE: ASM; USOTC: ATSMY) today announces that its Director of Communications, Dr Daniel Elger, will be presenting at the BIO CEO and Investor Conference in New York on Monday 12 February. Dr Elger's presentation will take place at 2.45pm EST.

A live webcast of the presentation can be viewed on Antisoma's website and will be available thereafter at [www.antisoma.com](http://www.antisoma.com). For the live webcast, it is recommended that viewers log on 15 minutes early in order to register and download any necessary software.

Dr Elger will also participate in a panel session entitled "Ovarian Cancer - Treatments Obviously Needed for a Not-So-Obvious Disease" on Monday 12 February at 3.30pm EST. Antisoma's presentation will consider the potential to improve outcomes in patients with ovarian cancer, focusing on combination therapy with the Company's vascular disrupting agent, AS1404.

**Enquiries:**

Katherine Harrison/Chris Elston  
Communications Manager

+44 (0)20 8799 8200

**Background on Antisoma**

Based in London, UK, Antisoma is a biopharmaceutical company that develops novel products for the treatment of cancer. Antisoma fills its development pipeline by acquiring promising new product candidates from internationally recognised academic or cancer research institutions. Its core activity is the preclinical and clinical development of these drug candidates. Please visit [www.antisoma.com](http://www.antisoma.com) for further information about Antisoma.

**Notification of Interim Results**

**London, UK: 30 January 2007**– Antisoma plc (LSE: ASM; USOTC: ATSMY) will be announcing its interim results for the six months ended 31 December 2006 on Thursday 15<sup>th</sup> February.

Enquiries:

Mark Court/Lisa Baderoon/Rebecca Skye Dietrich      +44 (0)20 7466 5000  
Buchanan Communications

*END*